Senthamizhchelvan Srinivasan

Dr. Senthamizhchelvan Srinivasan

Radiation Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2008 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
HVHansjörg Vees
Hansjörg Vees
SSSrinivasan Senthamizhchelvan
Srinivasan Senthamizhchelvan
RMRaymond Miralbell
Raymond Miralbell
DWDamien C. Weber
Damien C. Weber
OROsman Ratib
Osman Ratib
Habib ZaidiHabib Zaidi
Habib Zaidi

1 November 2009 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
HWHui Wang
Hui Wang
HVHansjörg Vees
Hansjörg Vees
RMRaymond Miralbell
Raymond Miralbell
MWMichael Wissmeyer
Michael Wissmeyer
CSCharles Steiner
Charles Steiner
Habib ZaidiHabib Zaidi
Habib Zaidi

29 November 2010 in Cancer
Verified
Journal Article
Open access
PDF file
DLDavid M. Loeb
David M. Loeb
RHRobert F. Hobbs
Robert F. Hobbs
AOAmarachukwu Okoli
Amarachukwu Okoli
ACAllen R. Chen
Allen R. Chen
SCSteve Cho
Steve Cho
CSCindy L. Schwartz
Cindy L. Schwartz
BACKGROUND: Samarium‐153 ethylenediamine tetramethylene phosphoric acid (153Sm‐EDTMP) is a radiopharmaceutical that has been used to treat osteosarcoma. The authors conducted a phase 2 study to test safety and response of high‐risk osteosarcoma to tandem doses of 153Sm‐EDTMP and to determine correlation between radiation delivered by low and high administered activities.METHODS: Patients with recurrent, refractory osteosarcoma detectable on standard 99mTc bone scan received a low dose of 153Sm‐EDTMP (37.0‐51.8 MBq/kg), followed upon count recovery by a second, higher dose (222 MBq/kg). Fourteen days later, patients were rescued with autologous hematopoietic stem cells. The authors assessed response to therapy, performed dosimetry to determine the relationship between administered activity and tumor absorbed dose, and investigated whether changes in 2‐(fluorine‐18) fluoro‐2‐deoxy‐d‐glucose (18F‐FDG) tumor uptake upon hematologic recovery reflected disease response.RESULTS: Nine patients were given tandem doses of 153Sm‐EDTMP; 2 received only the initial dose because of disease progression. Six patients experienced radiographic disease stabilization, but this was not considered a response, so the study was terminated early. There was a linear relationship between administered activity and tumor absorbed dose, but there was no correlation between change in 18F‐FDG positron emission tomography tumor uptake and tumor absorbed dose or time to progression. The median time to progression for the entire group was 79 days.CONCLUSIONS: Tandem doses of 153Sm‐EDTMP were safe for this cohort of heavily pretreated patients with very high‐risk disease. The strong correlation between absorbed dose and administered activity within each evaluable patient provides a methodology to individually tailor tandem doses of this agent. Cancer 2010. © 2010 American Cancer Society.

1 June 2009 in Physica Medica
Verified
Journal Article
Closed access
SSSrinivasan Senthamizhchelvan
Srinivasan Senthamizhchelvan
GPG.S. Pant
G.S. Pant
GRG.K. Rath
G.K. Rath
PJP.K. Julka
P.K. Julka
ONO. Nair
O. Nair

26 June 2012 in Antibodies
Verified
Journal Article
Open access
PDF file
HSHong Song
Hong Song
SSSrinivasan Senthamizhchelvan
Srinivasan Senthamizhchelvan
RHRobert F. Hobbs
Robert F. Hobbs
GSGeorge Sgouros
George Sgouros
Alpha-particle emitter labeled monoclonal antibodies are being actively developed for treatment of metastatic cancer due to the high linear energy transfer (LET) and the resulting greater biological efficacy of alpha-emitters. Our knowledge of high LET particle radiobiology derives primarily from accelerated heavy ion beam studies. In heavy ion beam therapy of loco-regional tumors, the modulation of steep transition to very high LET peak as the particle approaches the end of its track (known as the Bragg peak) enables greater delivery of biologically potent radiation to the deep seated tumors while sparing normal tissues surrounding the tumor with the relatively low LET track segment part of the heavy ion beam. Moreover, fractionation of the heavy ion beam can further enhance the peak-to-plateau relative biological effectiveness (RBE) ratio. In contrast, internally delivered alpha particle radiopharmaceutical therapy lack the control of Bragg peak energy deposition and the dose rate is determined by the administered activity, alpha-emitter half-life and biological kinetics of the radiopharmaceutical. The therapeutic ratio of tumor to normal tissue is mainly achieved by tumor specific targeting of the carrier antibody. In this brief overview, we review the radiobiology of high LET radiations learned from ion beam studies and identify the features that are also applicable for the development of alpha-emitter labeled antibodies. The molecular mechanisms underlying DNA double strand break repair response to high LET radiation are also discussed.

1 April 2013 in PET Clinics
Verified
Journal Article
Closed access
SSSrinivasan Senthamizhchelvan
Srinivasan Senthamizhchelvan
Habib ZaidiHabib Zaidi
Habib Zaidi